1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

27 Jul 2022
Admin
News Article

Sun Pharma Cosmo Expand License And Supply Agreements For Winlevi To Include Japan, Australia, New Zealand, Brazil, Mexico And Russia

Sun Pharmaceutical Industries Limited, World'S Fourth Largest Specialty Generic Pharmaceutical Company, And Cassiopea, A Subsidiary Of Cosmo Pharmaceuticals N.V Announced The Signing Of Addendums To The License And Supply Agreements For Winlevi (Clascoterone) Cream 1% Expanding The Territory To Include Japan, Australia, New Zealand, Brazil, Mexico And Russia.In 2021, Sun Pharma And Cassiopea Had Signed License And Supply Agreements For The United States And Canada Markets. Sun Pharma Launched Winlevi In The Us Market In November 2021.Under The Terms Of The Above Referred Agreements, Sun Pharma Will Receive From Cassiopea The Exclusive Right To Develop And Commercialize Winlevi In Japan, Australia, New Zealand, Brazil, Mexico And Russia. Cosmo Will Be The Exclusive Supplier Of The Product. Cassiopea Will Receive An Upfront Payment Of Us$ 7 Million, Potential Regulatory And Sales Milestones And Customary Double-Digit Royalties On Net Sales.Aalok Shanghvi, Evp & Head - Generic R&D, Generic Global Bd And Emerging Markets, Sun Pharma Said,

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!